Doug Boothe, CEO of Dexcel Pharma USA, stated: "We are excited to bring Nintedanib Capsules to market, further strengthening Dexcel's growing portfolio of specialty pharmaceutical products. This approval reflects our commitment to providing high-quality, accessible treatment options for patients. We look forward to working with our partners and customers to expand access to this important therapy."
About Dexcel Pharma USA
Dexcel Pharma USA is the U.S. subsidiary of Dexcel Pharma. Dexcel Pharma is the largest private pharmaceutical company in Israel, commercializing an extensive portfolio of branded and generic drugs. Our state-of-the-art R&D and manufacturing facilities enable us to develop and manufacture high-quality products while maintaining long-term partnerships across the value chain.
For more information please visit, www.dexcel-pharma-usa.com
